Nurix Therapeutics, Inc.
General ticker "NRIX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.4B (TTM average)
Nurix Therapeutics, Inc. follows the US Stock Market performance with the rate: 46.7%.
Estimated limits based on current volatility of 4.4%: low 16.70$, high 18.23$
Factors to consider:
- Total employees count: 286 as of 2024
- Top business risk factors: Drug development risks, Labor/talent shortage/retention, Operational and conduct risks, Regulatory and compliance, Cybersecurity threats
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-11-30 to 2027-11-30
- 2025-11-30 to 2026-11-30 estimated range: [8.93$, 22.10$]
- 2026-11-30 to 2027-11-30 estimated range: [7.36$, 18.91$]
Financial Metrics affecting the NRIX estimates:
- Negative: with PPE of -5.1 at the end of fiscal year the price was high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 11.10 > -0.60
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 78.29 > 64.29
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term NRIX quotes
Long-term NRIX plot with estimates
Financial data
| YTD | 2023-11-30 | 2024-11-30 | 2025-11-30 |
|---|---|---|---|
| Operating Revenue | $76.99MM | $54.55MM | $83.98MM |
| Operating Expenses | $232.05MM | $267.58MM | $369.65MM |
| Operating Income | $-155.06MM | $-213.03MM | $-285.67MM |
| Non-Operating Income | $11.12MM | $19.73MM | $21.97MM |
| R&D Expense | $189.15MM | $221.63MM | $316.90MM |
| Income(Loss) | $-143.95MM | $-193.30MM | $-263.70MM |
| Taxes | $0.00MM | $0.27MM | $0.76MM |
| Net Income(Loss)* | $-143.95MM | $-193.57MM | $-264.46MM |
| Stockholders Equity | $200.49MM | $526.99MM | $538.75MM |
| Assets | $355.60MM | $669.34MM | $688.13MM |
| Operating Cash Flow | $-81.36MM | $-172.58MM | $-249.47MM |
| Capital expenditure | $8.40MM | $9.27MM | $14.00MM |
| Investing Cash Flow | $68.30MM | $-257.71MM | $147.85MM |
| Financing Cash Flow | $3.22MM | $485.67MM | $238.64MM |
| Earnings Per Share** | $-2.65 | $-2.88 | $-3.05 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.